The Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm
Open Access
- 5 June 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1742
Abstract
Background/Objectives: Thoracic aortic aneurysm (TAA) often results from structural degeneration of the aortic wall. Traditional management focuses on hemodynamic control using beta-blockers (BB) and angiotensin receptor blockers (ARBs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for diabetes and weight management, may offer additional vascular protective benefits through anti-inflammatory, antioxidative, and matrix-stabilizing mechanisms. However, their role in reducing mortality and thoracic aortic dissection (TAD) risk in patients with TAA has not been evaluated in human populations. In this study, we aimed to assess the association between GLP-1 RA use and the risks of mortality and thoracic aortic dissection. Methods: We conducted a retrospective cohort study of adults diagnosed with TAA between 2018 and 2024 across three Mayo Clinic sites. Patients receiving GLP-1 RAs were compared with non-users using 1:1 propensity score matching. Outcomes included all-cause mortality, cardiovascular mortality, and incident TAD. Kaplan–Meier and Cox proportional hazards analyses were performed. Results: A total of 32,279 patients with TAA, with a median age of 68.0 [IQR: 59.0–76.0] and 70.7% male, were included in a 1:1 propensity score match. This yielded a balanced cohort of 588 GLP-1 RA users and 588 non-users. Through a median follow-up of 4.1 (2.2, 5.9) years, GLP-1 RA use was associated with significantly lower 5-year cumulative incidence of all-cause mortality (5.0% vs. 14.5%, HR: 0.31; 95% CI: 0.19–0.50; p < 0.001), cardiovascular mortality (1.9% vs. 5.5%, HR: 0.30; 95% CI: 0.13–0.70; p = 0.005), and TAD (0.9% vs. 4.0%, HR: 0.19; 95% CI: 0.06–0.60; p < 0.0004). Conclusions: GLP-1 RAs are associated with reduced incidence of all-cause mortality, cardiovascular mortality, and TAD incidence in patients with TAA. Prospective studies are needed to confirm these findings and evaluate effects on aneurysm progression.Keywords
This publication has 30 references indexed in Scilit:
- Aortic aneurysm: pathophysiology and therapeutic optionsMedcomm, 2024
- Matrix Metalloproteinase and Aortic Aneurysm: A Two-sample Mendelian Randomization StudyAnnals of Vascular Surgery, 2024
- The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic actionTrends in Cardiovascular Medicine, 2024
- Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE -/- miceBiochemical Pharmacology, 2024
- Glucagon-Like Peptide-1 Inhibits the Progression of Abdominal Aortic Aneurysm in Mice: The Earlier, the BetterCardiovascular Drugs and Therapy, 2023
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-artMolecular Metabolism, 2021
- Transforming Growth Factor-β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for TreatmentCardiovascular Drugs and Therapy, 2020
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- Beta-blockers for preventing aortic dissection in Marfan syndromeCochrane Database of Systematic Reviews, 2017
- Management of acute aortic dissectionThe Lancet, 2015